FSS | PUBLICATIONS
PUBLICATIONS
Explore articles based on work undertaken by Frontier Science Scotland
NordICC | The Lancet
Overview The Nordic-European Initiative on Colorectal Cancer (NordICC) study is a multinational,...
APHINITY | Journal of the National Cancer Institute
Benefits of adjuvant pertuzumab and trastuzumab in subgroups of the APHINITY trial by HER2 FISH ratio and ER status.
FLAIR | British Journal of Haematology
Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib–rituximab versus fludarabine–cyclophosphamide–rituximab
COLONIZE | Annals of Internal Medicine
Fecal Microbiota Transplantation Versus Vancomycin for Primary Clostridioides difficile Infection
APHINITY | European Journal of Cancer
Body mass index and weight changes in patients with HER2-positive early
breast cancer: A sub-analysis of the APHINITY trial
ALEXANDRA | Journal of the American Medical Association (JAMA)
The addition of the immune therapy drug atezolizumab to chemotherapy after surgery did not provide benefit among patients with triple-negative breast cancer who are at high risk of recurrent disease.
ALTTO | ESMO Open
Final 10-year analysis of the ALTTO trial exploring dual anti-HER2 blockade with lapatinib + trastuzumab compared to trastuzumab alone.
APHINITY | Journal of Clinical Oncology
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update
OlympiA results in the subset of patients from Japan
The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.